80/100B160.420
USD
-2.88
(-1.76%)
Pre Open
Last updated: · Delayed 15 min
Fair value128.72Plus+25%103Price 160.42634
Q4 FY2026 · Earnings report
EPS estimate 2.23Revenue estimate 14.65B
Q4 FY2026 · Earnings report
EPS estimate 2.23Revenue estimate 14.65B
Novartis revenue 1998–2026What is revenue? Revenue is the money a company brings in from selling its goods and services over a period, before any costs. It is the top line of the income statement.
Novartis's revenue in Q3 FY2026, the three months to 30 September 2026, was 15.03B USD, up 4.7% on the same quarter a year before. Novartis's revenue over the last twelve months was 56.31B USD, down 0.1% on the twelve months before. In fiscal year 2025 it was 54.81B USD, up 6.0% on the year before.
Last updated 8 Nov 2026 · Next report 3 Feb 2027
Revenue
Growth
| Fiscal year | Period ending | Revenue | Growth | Gross profit | Net income |
|---|---|---|---|---|---|
| TTM | 30 Sept 2026 | 56.31B | -0.12% | 42.02B | 10.03B |
| FY2025 | 31 Dec 2025 | 54.81B | +5.97% | 41.12B | 13.98B |
| FY2024 | 31 Dec 2024 | 51.72B | +10.85% | 38.90B | 11.94B |
| FY2023 | 31 Dec 2023 | 46.66B | +7.36% | 34.19B | 14.85B |
| FY2022 | 31 Dec 2022 | 43.46B | -1.17% | 31.88B | 6.96B |
| FY2021 | 31 Dec 2021 | 43.97B | -11.87% | 32.24B | 24.02B |
| FY2020 | 31 Dec 2020 | 49.90B | +2.51% | 34.78B | 8.07B |
| FY2019 | 31 Dec 2019 | 48.68B | +5.59% | 34.25B | 11.73B |
| FY2018 | 31 Dec 2018 | 46.10B | +6.21% | 31.59B | 12.61B |
| FY2017 | 31 Dec 2017 | 43.40B | -12.20% | 29.77B | 7.70B |
| FY2016 | 31 Dec 2016 | 49.44B | -1.89% | 31.92B | 6.71B |
| FY2015 | 31 Dec 2015 | 50.39B | -6.05% | 32.98B | 17.78B |
| FY2014 | 31 Dec 2014 | 53.63B | +1.74% | 36.29B | 10.21B |
| FY2013 | 31 Dec 2013 | 52.72B | +1.43% | 36.14B | 9.18B |
| FY2012 | 31 Dec 2012 | 51.97B | -12.47% | 36.11B | 9.27B |
| FY2011 | 31 Dec 2011 | 59.38B | +15.15% | 40.39B | 8.94B |
| FY2010 | 31 Dec 2010 | 51.56B | +14.32% | 37.07B | 9.79B |
| FY2009 | 31 Dec 2009 | 45.10B | +5.92% | 32.92B | 8.40B |
| FY2008 | 31 Dec 2008 | 42.58B | +9.34% | 31.15B | 8.20B |
| FY2007 | 31 Dec 2007 | 38.95B | +10.94% | 27.92B | 11.95B |
| FY2006 | 31 Dec 2006 | 35.11B | +17.99% | 25.69B | 7.18B |
| FY2005 | 31 Dec 2005 | 29.75B | +9.08% | 22.31B | 6.13B |
| FY2004 | 31 Dec 2004 | 27.28B | +9.41% | 20.58B | 5.37B |
| FY2003 | 31 Dec 2003 | 24.93B | +19.41% | 18.47B | 4.74B |
| FY2002 | 31 Dec 2002 | 20.88B | +11.27% | 15.88B | 4.73B |
| FY2001 | 31 Dec 2001 | 18.76B | -15.43% | 14.02B | 3.84B |
| FY2000 | 31 Dec 2000 | 22.19B | +8.83% | 15.84B | 4.47B |
| FY1999 | 31 Dec 1999 | 20.39B | -11.52% | 15.17B | 4.18B |
| FY1998 | 31 Dec 1998 | 23.04B | — | 15.73B | 4.37B |
| Quarter | Period ending | Revenue | Growth on a year before | Gross profit | Net income |
|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 15.03B | +4.67% | 11.42B | 1.20B |
| Q2 FY2026 | 30 Jun 2026 | 14.42B | -2.82% | 10.74B | 3.27B |
| Q1 FY2026 | 31 Mar 2026 | 13.52B | -0.70% | 10.07B | 3.16B |
| Q4 FY2025 | 31 Dec 2025 | 13.33B | -1.64% | 9.79B | 2.41B |
| Q3 FY2025 | 29 Sept 2025 | 14.36B | +9.00% | 10.82B | 3.93B |
| Q2 FY2025 | 30 Jun 2025 | 14.84B | +15.26% | 11.51B | 4.04B |
| Q1 FY2025 | 31 Mar 2025 | 13.62B | +12.38% | 10.39B | 3.61B |
| Q4 FY2024 | 31 Dec 2024 | 13.56B | +15.13% | 10.23B | 2.82B |
| Q3 FY2024 | 30 Sept 2024 | 13.17B | +8.93% | 9.94B | 3.19B |
| Q2 FY2024 | 30 Jun 2024 | 12.87B | +9.60% | 9.70B | 3.25B |
| Q1 FY2024 | 31 Mar 2024 | 12.12B | +9.71% | 9.02B | 2.69B |
| Q4 FY2023 | 31 Dec 2023 | 11.78B | -10.02% | 8.75B | 8.48B |
| Q3 FY2023 | 30 Sept 2023 | 12.09B | +12.14% | 8.98B | 1.76B |
| Q2 FY2023 | 30 Jun 2023 | 11.75B | -10.24% | 8.40B | 2.32B |
| Q1 FY2023 | 31 Mar 2023 | 11.05B | -13.79% | 8.06B | 2.29B |
| Q4 FY2022 | 31 Dec 2022 | 13.09B | -3.22% | 9.01B | 1.47B |
| Q3 FY2022 | 30 Sept 2022 | 10.78B | -19.33% | 7.91B | 1.57B |
| Q2 FY2022 | 30 Jun 2022 | 13.09B | -1.57% | 9.33B | 1.69B |
| Q1 FY2022 | 31 Mar 2022 | 12.81B | +0.95% | 8.96B | 2.22B |
| Q4 FY2021 | 31 Dec 2021 | 13.52B | +3.78% | 9.55B | 16.31B |
| Q3 FY2021 | 30 Sept 2021 | 13.37B | +6.61% | 9.43B | 2.76B |
| Q2 FY2021 | 30 Jun 2021 | 13.29B | +14.39% | 9.38B | 2.90B |
| Q1 FY2021 | 31 Mar 2021 | 12.69B | -0.11% | 8.66B | 2.06B |
| Q4 FY2020 | 31 Dec 2020 | 13.03B | +2.47% | 8.81B | 2.09B |
| Q3 FY2020 | 30 Sept 2020 | 12.54B | +0.45% | 8.79B | 1.94B |
| Q2 FY2020 | 30 Jun 2020 | 11.62B | -3.34% | 8.19B | 1.87B |
| Q1 FY2020 | 31 Mar 2020 | 12.71B | +10.94% | 8.99B | 2.18B |
| Q4 FY2019 | 31 Dec 2019 | 12.72B | -6.94% | 8.72B | 1.13B |
| Q3 FY2019 | 30 Sept 2019 | 12.48B | +9.63% | 8.71B | 2.04B |
| Q2 FY2019 | 30 Jun 2019 | 12.02B | +3.18% | 8.62B | 6.80B |
| Q1 FY2019 | 31 Mar 2019 | 11.46B | +2.62% | 8.20B | 1.77B |
| Q4 FY2018 | 31 Dec 2018 | 13.66B | +3.80% | 8.74B | 1.20B |
| Q3 FY2018 | 30 Sept 2018 | 11.39B | -10.29% | 7.92B | 1.62B |
| Q2 FY2018 | 30 Jun 2018 | 11.65B | -6.73% | 8.10B | 7.77B |
| Q1 FY2018 | 31 Mar 2018 | 11.16B | -5.28% | 7.71B | 2.03B |
| Q4 FY2017 | 31 Dec 2017 | 13.16B | +4.43% | 8.68B | 1.98B |
| Q3 FY2017 | 30 Sept 2017 | 12.69B | +2.84% | 8.37B | 2.08B |
| Q2 FY2017 | 30 Jun 2017 | 12.49B | -1.46% | 8.24B | 1.98B |
| Q1 FY2017 | 31 Mar 2017 | 11.79B | -0.21% | 7.68B | 1.67B |
| Q4 FY2016 | 31 Dec 2016 | 12.61B | -1.55% | 8.12B | 957.00M |
| Q3 FY2016 | 30 Sept 2016 | 12.34B | -1.15% | 7.97B | 1.94B |
| Q2 FY2016 | 30 Jun 2016 | 12.68B | -1.68% | 8.23B | 1.80B |
| Q1 FY2016 | 31 Mar 2016 | 11.81B | -3.21% | 7.60B | 2.01B |
| Q4 FY2015 | 31 Dec 2015 | 12.80B | -4.12% | 8.26B | 1.05B |
| Q3 FY2015 | 30 Sept 2015 | 12.49B | -6.13% | 8.10B | 1.89B |
| Q2 FY2015 | 30 Jun 2015 | 12.90B | -7.55% | 8.41B | 1.84B |
| Q1 FY2015 | 31 Mar 2015 | 12.20B | -6.36% | 8.22B | 13.01B |
| Q4 FY2014 | 31 Dec 2014 | 13.35B | -13.08% | 8.94B | 1.49B |
| Q3 FY2014 | 30 Sept 2014 | 13.30B | +3.05% | 8.88B | 3.22B |
| Q2 FY2014 | 30 Jun 2014 | 13.95B | +5.04% | 9.57B | 2.56B |
| Q1 FY2014 | 31 Mar 2014 | 13.03B | -8.27% | 8.90B | 2.94B |
| Q4 FY2013 | 31 Dec 2013 | 15.36B | +1.96% | 10.05B | 2.03B |
| Q3 FY2013 | 30 Sept 2013 | 12.91B | -8.07% | 8.78B | 2.23B |
| Q2 FY2013 | 30 Jun 2013 | 13.28B | -8.67% | 9.19B | 2.52B |
| Q1 FY2013 | 31 Mar 2013 | 14.21B | +2.11% | 9.60B | 2.40B |
| Q4 FY2012 | 31 Dec 2012 | 15.07B | +0.48% | 9.98B | 2.05B |
| Q3 FY2012 | 30 Sept 2012 | 14.04B | -6.62% | 9.46B | 2.39B |
| Q2 FY2012 | 30 Jun 2012 | 14.54B | -3.85% | 9.93B | 2.65B |
| Q1 FY2012 | 31 Mar 2012 | 13.91B | -2.17% | 9.43B | 2.25B |
| Q4 FY2011 | 31 Dec 2011 | 15.00B | +3.68% | 9.88B | 1.18B |
| Q3 FY2011 | 30 Sept 2011 | 15.03B | +17.27% | 10.25B | 2.46B |
| Q2 FY2011 | 30 Jun 2011 | 15.12B | +26.86% | 10.50B | 2.70B |
| Q1 FY2011 | 31 Mar 2011 | 14.22B | +15.10% | 9.76B | 2.77B |
| Q4 FY2010 | 31 Dec 2010 | 14.46B | +10.03% | 9.94B | 2.17B |
| Q3 FY2010 | 30 Sept 2010 | 12.82B | +13.55% | 9.16B | 2.28B |
| Q2 FY2010 | 30 Jun 2010 | 11.92B | +10.98% | 8.72B | 2.42B |
| Q1 FY2010 | 31 Mar 2010 | 12.36B | +24.48% | 9.26B | 2.93B |
| Q4 FY2009 | 31 Dec 2009 | 13.15B | +27.03% | 9.48B | 2.31B |
| Q3 FY2009 | 30 Sept 2009 | 11.29B | +2.36% | 8.19B | 2.10B |
| Q2 FY2009 | 30 Jun 2009 | 10.74B | -2.26% | 7.92B | 2.04B |
| Q1 FY2009 | 31 Mar 2009 | 9.93B | -2.84% | 7.12B | 1.96B |
| Q4 FY2008 | 31 Dec 2008 | 10.35B | +1.74% | 7.51B | 1.54B |
| Q3 FY2008 | 30 Sept 2008 | 11.03B | +12.34% | 8.01B | 2.09B |
| Q2 FY2008 | 30 Jun 2008 | 10.99B | +16.91% | 8.05B | 2.25B |
| Q1 FY2008 | 31 Mar 2008 | 10.22B | +8.98% | 7.57B | 2.32B |
| Q4 FY2007 | 31 Dec 2007 | 10.17B | +9.14% | 7.16B | 904.00M |
| Q3 FY2007 | 30 Sept 2007 | 9.82B | +8.80% | 6.78B | 6.87B |
| Q2 FY2007 | 30 Jun 2007 | 9.40B | +10.48% | 6.90B | 2.01B |
| Q1 FY2007 | 31 Mar 2007 | 9.37B | +15.02% | 6.89B | 2.17B |
| Q4 FY2006 | 31 Dec 2006 | 9.32B | +6.47% | 6.81B | 1.65B |
| Q3 FY2006 | 30 Sept 2006 | 9.02B | +6.30% | 6.50B | 1.87B |
| Q2 FY2006 | 30 Jun 2006 | 8.51B | +8.11% | 6.28B | 1.71B |
| Q1 FY2006 | 31 Mar 2006 | 8.15B | +11.02% | 5.97B | 1.95B |
| Q4 FY2005 | 31 Dec 2005 | 8.75B | +15.51% | 6.24B | 1.35B |
| Q3 FY2005 | 30 Sept 2005 | 8.49B | +20.29% | 6.04B | 1.66B |
| Q2 FY2005 | 30 Jun 2005 | 7.87B | +12.86% | 5.90B | 1.65B |
| Q1 FY2005 | 31 Mar 2005 | 7.34B | +10.57% | 5.49B | 1.48B |
| Q4 FY2004 | 31 Dec 2004 | 7.58B | +12.60% | 5.70B | 1.38B |
| Q3 FY2004 | 30 Sept 2004 | 7.06B | +13.64% | 5.44B | 1.55B |
| Q2 FY2004 | 30 Jun 2004 | 6.97B | +12.41% | 5.38B | 1.55B |
| Q1 FY2004 | 31 Mar 2004 | 6.64B | +16.05% | 5.10B | 1.29B |
| Q4 FY2003 | 31 Dec 2003 | 6.73B | -13.77% | 5.12B | 1.36B |
| Q3 FY2003 | 30 Sept 2003 | 6.21B | +22.75% | 4.71B | 1.28B |
| Q2 FY2003 | 30 Jun 2003 | 6.20B | +10.81% | 4.78B | 1.32B |
| Q1 FY2003 | 31 Mar 2003 | 5.72B | +17.76% | 4.36B | 1.06B |
| Q4 FY2002 | 31 Dec 2002 | 7.81B | +51.91% | 6.05B | 1.68B |
| Q3 FY2002 | 30 Sept 2002 | 5.06B | -9.27% | 3.85B | 1.11B |
| Q2 FY2002 | 30 Jun 2002 | 5.60B | +29.85% | 4.30B | 1.39B |
| Q1 FY2002 | 31 Mar 2002 | 4.86B | +9.41% | 0.00 | 1.09B |
| Q4 FY2001 | 31 Dec 2001 | 5.14B | -13.81% | 0.00 | 1.03B |
| Q3 FY2001 | 30 Sept 2001 | 5.58B | +14.24% | 0.00 | 1.13B |
| Q2 FY2001 | 30 Jun 2001 | 4.31B | +0.77% | 3.25B | 1.04B |
| Q1 FY2001 | 31 Mar 2001 | 4.44B | -22.06% | 0.00 | 1.07B |
| Q4 FY2000 | 31 Dec 2000 | 5.96B | — | 0.00 | 1.09B |
| Q3 FY2000 | 30 Sept 2000 | 4.88B | — | 0.00 | 876.00M |
| Q2 FY2000 | 30 Jun 2000 | 4.28B | — | 3.22B | 1.28B |
| Q1 FY2000 | 31 Mar 2000 | 5.70B | — | 0.00 | 1.26B |
Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
Novartis revenue growth by segment
Q2 FY2023 against Q2 FY2022
Top 20 products8.79B
+6.4%
Rest of portfolio2.45B
+11.6%
Novartis revenue by segment over time
Top 20 products Rest of portfolio Total anti-infectives net sales Anti Infectives sold under Sandoz name COPD
See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement
Common questions about Novartis's revenue
Source: Financial Modeling Prep